FIG E3. Effects of other therapies in addition to TCSs on long-term remodeling features. Epithelial eosinophil counts **(A)** and remodeling **(B)** and LP eosinophil counts **(C)** and FSs **(D)** in all subjects receiving any therapy (including TCSs, oral corticosteroids, elimination diet, and/or biologics) during the study time period are shown. Epithelial eosinophil counts **(E)** and LP FSs **(F)** in subjects who did versus did not receive other therapies in addition to TCSs. *Bars* represent mean data ± SEMs for all subjects on all therapies through the entire study period.

FIG E4. FSs in responders *(left)* and nonresponders *(right)* filtered by TCS use. *Bars* represent mean data ± SEMs for all subjects through the entire study period.

FIG E5. Overall FS and EGD scores are lower when inflammation is better controlled. Final FSs and final EGD scores in subjects who have less than 15, 15 to 50, or more than >50 eosinophils/hpf over their disease duration are shown. *Bars* represent mean data ± SEMs for all subjects through the entire study period.

FIG E6. Asthmatic patients have higher epithelial eosinophil counts than those without asthma. Graphs show means $\pm$ SEMs of baseline epithelial eosinophils in the total population with and without asthma.

TABLE E1. Correlation coefficients when comparing mean epithelial eosinophil count with LP FSs, epithelial remodeling scores, LP eosinophil counts, TGF-β1 cell counts, epithelial eosinophilia, EGD scores, and symptom scores

Time (y)	Epithelial remodeling score	LP eosinophil count	LP FS	TGF-β1 cell count	EGD score	Symptom score
0	$r = 0.36, P = .0587$	$r = 0.19, P = .3249$	$r = 0.32, P = .09$	$r = 0.21, P = .275$	$r = 0.31, P = .0981$	$r = -0.07, P = .725$
1.21	$r = 0.87, P < .0001$	$r = 0.80, P < .0001$	$r = 0.79, P < .0001$	$r = 0.33, P = .063$	$r = 0.72, P < .0001$	$r = 0.30, P = .098$
2.58	$r = 0.86, P < .0001$	$r = 0.63, P = .0002$	$r = 0.59, P = .0013$	$r = 0.17, P = .3576$	$r = 0.65, P < .0001$	$r = -0.12, P = .504$
4.05	$r = 0.73, P < .0001$	$r = 0.52, P = .0012$	$r = 0.49, P = .0022$	$r = -0.30, P = .0632$	$r = 0.70, P < .0001$	$r = 0.37, P = .0221$
5.56	$r = 0.94, P < .0001$	$r = 0.75, P = .0062$	$r = 0.56, P = .0614$	$r = -0.51, P = .0515$	$r = 0.86, P < .0001$	$r = 0.40, P = .1385$
Overall	$r = 0.82, P < .0001$	$r = 0.60, P < .0001$	$r = 0.59, P < .0001$	$r = 0.07, P = .4212$	$r = 0.67, P < .0001$	$r = 0.22, P = .006$

TABLE E2. Correlation coefficients when comparing LP FSs with epithelial remodeling scores, LP eosinophil counts, TGF-β1 cell counts, epithelial eosinophilia, EGD scores, and symptom scores

Time (y)	Epithelial remodeling score	LP eosinophil count	TGF-β1 cell count	Epithelial eosinophilia	EGD score	Symptom score
0	$r = 0.25, P = .19$	$r = 0.03, P = .88$	$r = 0.21, P = .27$	$r = 0.19, P = .3$	$r = 0.15, P = .444$	$r = 0.05, P = .797$
1.21	$r = 0.82, P < .0001$	$r = 0.71, P < .0001$	$r = 0.47, P < .014$	$r = 0.77, P < .0001$	$r = 0.88, P < .0001$	$r = 0.21, P = .294$
2.58	$r = 0.79, P < .0001$	$r = 0.61, P = .0008$	$r = 0.09, P = .65$	$r = 0.58, P = .0015$	$r = 0.55, P = .003$	$r = -0.30, P = .125$
4.05	$r = 0.57, P = .0002$	$r = 0.34, P = .0427$	$r = -0.03, P = .83$	$r = 0.41, P = .0116$	$r = 0.36, P = .0298$	$r = 0.23, P = .175$
5.56	$r = 0.64, P = .0319$	$r = 0.30, P = .349$	$r = -0.30, P = .21$	$r = 0.62, P = .035$	$r = 0.44, P = .146$	$r = 0.16, P = .617$
Overall	$r = 0.64, P < .0001$	$r = 0.44, P < .0001$	$r = 0.18, P = .035$	$r = 0.53, P < .0001$	$r = 0.54, P < .0001$	$r = 0.10, P = .24$